Top Markets
Coin of the day
Talaris Therapeutics, Inc. Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc.

TALS
Clasificación en acciones #21258
Talaris Therapeutics, Inc. is a cell therapy company operating in the United... Talaris Therapeutics, Inc. is a cell therapy company operating in the United States, currently in its late clinical development stages. Its mission involves pioneering an allogeneic hematopoietic stem cell transplantation strategy designed to revolutionize treatment paradigms for solid organ transplantation, severe autoimmune conditions, and significant non-malignant blood, immune, and metabolic disorders. The company's flagship product, FCR001, is an innovative allogeneic cell therapy presently in Phase II clinical trials for patients undergoing living donor kidney transplantation. Beyond this, Talaris Therapeutics is actively advancing FCR002 for use in deceased donor kidney transplants, investigating FCR001 for individuals with a severe form of scleroderma, and exploring its applicability for a range of other serious non-malignant blood, immune, or metabolic conditions. Founded in 1988, the company maintains its headquarters in Louisville, Kentucky.
Precio por acción
$2.72
Última sincronización: 2023-10-19
Capitalización bursátil
$111.47M
Cambio (1 día)
-0.73%
Cambio (1 año)
0.00%
País
US
Comercio Talaris Therapeutics, Inc. (TALS)

Categoría

Ratio P/B de Talaris Therapeutics, Inc. (TALS)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Talaris Therapeutics, Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Talaris Therapeutics, Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH